Company News: Zydus Cadila

| Updated on April 19, 2018 Published on April 19, 2018

Zydus Cadila has received final approval from the US health regulator to market Diclofenac Sodium Topical Solution, used for treating signs and symptoms of osteoarthritis of the knees, said Cadila Healthcare in a notice to the stock exchanges. It is a non-steroidal anti-inflammatory drug. The drug will be produced at the group’s topical manufacturing facility at Ahmedabad, the company added. The Zydus group has more than 185 approvals, and has, so far, filed over 320 abbreviated new drug applications (ANDAs) since it started filings in 2003-04. Shares of Cadila Healthcare closed 0.66 per cent higher at ₹387.65 on the NSE.

Published on April 19, 2018
This article is closed for comments.
Please Email the Editor